Ficonalkib

Ficonalkib is a potent antineoplastic agent that inhibits the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor, used as an anticancer agent in the treatment of ALK-driven malignancies. As an orally bioavailable, third-generation inhibitor of ALK, Ficonalkib demonstrates IC₅₀ values of 1.3 nM and 1.5 nM for wild-type ALK and the F1174L mutant, respectively. Ficonalkib binds to and inhibits ALK wild-type tyrosine kinase and numerous ALK mutations, including acquired resistance mutations, leading to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. Ficonalkib belongs to the third generation of ALK inhibitors, designed to overcome resistance mechanisms that limit the efficacy of earlier-generation ALK inhibitors such as crizotinib, ceritinib, and alectinib. With its high kinase selectivity profile, Ficonalkib represents a promising therapeutic option for patients with ALK-positive NSCLC who have progressed on prior ALK inhibitor therapies.

 

Product Parameters

---

Parameter	Specification
Product Name	Ficonalkib
CAS Number	2233574-95-1
Molecular Formula	C₂₉H₃₉N₇O₃S
Molecular Weight	565.73 g/mol
Appearance	Light yellow to brown solid
Boiling Point	781.1±70.0℃
Density	1.32±0.1 g/cm3
Storage Condition	−20 °C

Product Advantages

---

 Potent Third-Generation ALK Inhibitor

Ficonalkib is a potent, selective, third-generation ALK inhibitor with IC₅₀ values of 1.3 nM for wild-type ALK and 1.5 nM for the F1174L mutant. This exceptional potency makes Ficonalkib a leading candidate for ALK-positive NSCLC and other ALK-driven malignancies.

 

 Broad Coverage of ALK Resistance Mutations

Ficonalkib binds to and inhibits ALK wild-type tyrosine kinase and numerous ALK mutations, including acquired resistance mutations. This broad coverage makes Ficonalkib effective in patients who have progressed on earlier-generation ALK inhibitors.

 

 High Kinase Selectivity

Ficonalkib exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK) family members (TRKA-C). This selectivity profile suggests a favorable safety and tolerability profile compared to less selective ALK inhibitors.

 

 Orally Bioavailable

Ficonalkib is orally bioavailable, supporting convenient oral dosing in clinical applications. This pharmacokinetic property is critical for patient adherence and chronic dosing in oncology indications.

 

 Advanced Pyrrolopyrimidine Scaffold

The pyrrolo[2,3-d]pyrimidine core of Ficonalkib represents a sophisticated class of kinase inhibitors. The compound's complex architecture requires advanced synthetic capabilities—expertise that Cosperpharm brings to every batch.

 

Product Quality Assurance

---

Cosperpharm has established a comprehensive quality assurance system for Ficonalkib that meets the rigorous expectations of both research compound manufacturing and reference standard applications:

 

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity (≥98%), appearance verification (light yellow to brown solid powder), water content determination (Karl Fischer), residual solvent analysis (GC), and where applicable, ¹H NMR and MS confirmation of molecular identity.

 

Full batch traceability with retention samples. From raw material procurement through synthesis, purification, drying, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

 

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions: long-term storage at −20 °C, with accelerated stability studies conducted on representative batches. Stability summaries are updated regularly, with full data packages available to support customer regulatory submissions. Shelf life: 3 years at −20 °C; 2 years at 4 °C.

 

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. Custom quality agreements and additional documentation are available upon request.

 

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

 

FAQ

---

Q1: What is Ficonalkib?

A: Ficonalkib (CAS 2233574-95-1, SY-3505) is a potent, selective, third-generation inhibitor of anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase implicated in various malignancies, particularly non-small cell lung cancer (NSCLC).

 

Q2: What is the mechanism of action of Ficonalkib?

A: Ficonalkib binds to and inhibits ALK wild-type tyrosine kinase and numerous ALK mutations, including acquired resistance mutations. This inhibition disrupts ALK-mediated signaling and inhibits cell growth in ALK-expressing tumor cells.

 

Contact Us

---

Need Ficonalkib for your ALK inhibitor research program, preclinical development, or manufacturing campaign? Cosperpharm is your trusted partner for high-purity research compounds and reference standards. Reach out today—our team is ready to support your project from discovery through clinical development.